Pricing Log in Create free account
Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS
−19.6%
Free cash flow
−43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%
Market cap
$6.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
0.00%
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Oruka Therapeutics, Inc. (ORKA) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 26, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 24, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
10-Q Jun 30, 2026 P1I2: 17 added · 2 removed · 28 modified
P2I1A: 12 modified 		Share dilution
8-K Aug 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 2, 2026 5.07 Submission of matters to a vote of security holders
8-K May 29, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 27, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 27, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 36 added · 47 removed · 90 modified
1A: 13 added · 18 removed · 120 modified
7: 30 added · 27 removed · 46 modified
8-K Dec 11, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Sep 17, 2025 1.01 Entry into a material definitive agreement; 3.02 Unregistered sales of equity securities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-Q Mar 31, 2025
10-K Dec 31, 2024
10-Q Sep 30, 2024
8-K Aug 29, 2024 1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.02 Results of operations and financial condition; 3.03 Material modification of shareholders' rights; 4.01 Change in the certifying accountant; 5.01 Change in control; 5.02 Departure or appointment of directors or officers; 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.05 Amendments to the code of ethics; 5.06 Change in shell company status; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Apr 25, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.